Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
61
ANAB Quote, Financials, Valuation and Earnings
Last price:
$50.09
Seasonality move
:
-2.57%
Day range:
$49.79 - $50.90
52-week range:
$12.21 - $51.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.79x
P/B ratio:
17.29x
Volume:
407K
Avg. volume:
574.6K
1-year change:
260.04%
Market cap:
$1.4B
Revenue:
$91.3M
EPS (TTM):
-$2.82
Analysts' Opinion
-
Consensus RatingAnaptysBio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $65.09, AnaptysBio, Inc. has an estimated upside of 30.08% from its current price of $50.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $50.01.
Fair Value
-
According to the consensus of 9 analysts, AnaptysBio, Inc. has 30.08% upside to fair value with a price target of $65.09 per share.
ANAB vs. S&P 500
-
Over the past 5 trading days, AnaptysBio, Inc. has overperformed the S&P 500 by 9.56% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AnaptysBio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AnaptysBio, Inc. has grown year-over-year revenues for 12 quarters straight. In the most recent quarter AnaptysBio, Inc. reported revenues of $76.3M.
Earnings Growth
-
AnaptysBio, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter AnaptysBio, Inc. reported earnings per share of $0.52.
Enterprise value:
1.5B
EV / Invested capital:
4.68x
Price / LTM sales:
8.79x
EV / EBIT:
--
EV / Revenue:
8.75x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
-10.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$167M
Return On Assets:
-20.27%
Net Income Margin (TTM):
-49.94%
Return On Equity:
-367.62%
Return On Invested Capital:
-22.38%
Operating Margin:
45.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $15M | $57.2M | $169.5M | $30M | $76.3M | |
| Gross Profit | $12.6M | $54.8M | $167M | $29.4M | $75.7M | |
| Operating Income | -$148.2M | -$140.1M | -$28.7M | -$22.8M | $34.7M | |
| EBITDA | -$145.9M | -$137.7M | -$26.3M | -$22.2M | $35.3M | |
| Diluted EPS | -$5.41 | -$6.07 | -$2.82 | -$1.14 | $0.52 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $386.6M | $450.4M | $428M | $448.7M | $330.7M | |
| Total Assets | $424.3M | $618.5M | $487.3M | $493.4M | $353.1M | |
| Current Liabilities | $20.9M | $21.1M | $39.2M | $43.9M | $38.1M | |
| Total Liabilities | $40.7M | $340.9M | $366.9M | $409.1M | $382.5M | |
| Total Equity | $383.6M | $277.6M | $120.4M | $84.4M | -$29.4M | |
| Total Debt | $20.9M | $319.8M | $327.8M | $365.2M | $344.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$97.1M | -$103.1M | -$145.1M | -$10.1M | -$27.4M | |
| Cash From Investing | $117.1M | $174M | $125.1M | $58.6M | $103.3M | |
| Cash From Financing | -$52.2M | $94.4M | -$61.8M | $71.2M | -$10.4M | |
| Free Cash Flow | -$97.8M | -$103.4M | -$145.4M | -$10.1M | -$27.4M | |
ANAB
Sector
Market Cap
$1.4B
$28.1M
Price % of 52-Week High
97.4%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
8.26%
-1.49%
1-Year Price Total Return
258.2%
-17.13%
Beta (5-Year)
0.286
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$47.27
200-day SMA
Buy
Level
$26.39
Bollinger Bands (100)
Buy
Level
21.97 - 40.55
Chaikin Money Flow
Buy
Level
19.9M
20-day SMA
Buy
Level
$44.81
Relative Strength Index (RSI14)
Buy
Level
76.01
ADX Line
Buy
Level
34.18
Williams %R
Sell
Level
-15.7865
50-day SMA
Buy
Level
$39.31
MACD (12, 26)
Buy
Level
3.04
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
19.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2478)
Sell
CA Score
(Annual)
Level (-3.0122)
Sell
Beneish M-Score
(Annual)
Level (1.4084)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (3.3899)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, ANAB has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ANAB average analyst price target in the past 3 months is $65.09.
-
Where Will AnaptysBio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that AnaptysBio, Inc. share price will rise to $65.09 per share over the next 12 months.
-
What Do Analysts Say About AnaptysBio, Inc.?
Analysts are divided on their view about AnaptysBio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AnaptysBio, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is AnaptysBio, Inc.'s Price Target?
The price target for AnaptysBio, Inc. over the next 1-year time period is forecast to be $65.09 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ANAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AnaptysBio, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANAB?
You can purchase shares of AnaptysBio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AnaptysBio, Inc. shares.
-
What Is The AnaptysBio, Inc. Share Price Today?
AnaptysBio, Inc. was last trading at $50.09 per share. This represents the most recent stock quote for AnaptysBio, Inc.. Yesterday, AnaptysBio, Inc. closed at $50.01 per share.
-
How To Buy AnaptysBio, Inc. Stock Online?
In order to purchase AnaptysBio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ANAB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANAB
Sector
P/E ratio
--
23.89x
PEG ratio
-0.20x
-0.01x
P/B ratio
17.29x
1.81x
Price / LTM sales
8.79x
1.59x
Growth Metrics
ANAB
Sector
Revenue growth
154.26%
4.62%
Earnings growth
145.81%
11.06%
Revenue (5-year growth)
62.73%
6.5%
Earnings forecast
-$1.25
-$0.21
Profitability
ANAB
Sector
Profitability FY 2024
$88.9M
$3.6M
Return on invested capital
-22.38%
-31.84%
Return on assets
-20.27%
-27.96%
Return on equity
-367.62%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
ANAB
Sector
Total cash
$249M
$26.4M
Short term investments
$262.3M
$25.7M
Total assets
$483.8M
$76.9M
Long term debt
$344.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
